The association between body mass index (BMI) and BRAFV600E mutation may differ by primary tumor size
Authors' conclusion
Our study found that a higher BMI was positively associated with the BRAFV600E mutation in patients with a primary tumor size >1 cm. These results suggest that the association between BMI and the BRAFV600E mutation status differs depending on primary tumor size.
Study context
- Population
- PTC patients who had undergone BRAFV600E mutation testing, January 2009–December 2017; 76.9% female; median BMI 23.8 (21.6–26.2) kg/m²6,558 screened
- Participants
- 6,438 patients
- Exposure
- Association of BMI with BRAFV600E mutation, by primary tumour size
- Tumor size >1 cmn = 2,212
- Tumor size ≤1 cmn = 4,226
- Outcome
- BRAFV600E mutation (association with BMI, logistic regression)
Main finding
As reported in the abstract
Association of high BMI with BRAFV600E mutation, by primary tumor size
| Group | OR |
|---|---|
| Tumor size >1 cm | 1.034 (95% CI 1.003-1.065; P = 0.029) |
| Tumor size ≤1 cm | 1.007 (95% CI 0.984-1.030; P = 0.570) |
OR
Tumor size >1 cm1.034 (95% CI 1.003-1.065; P = 0.029)
Tumor size ≤1 cm1.007 (95% CI 0.984-1.030; P = 0.570)
Observational data: associations, not effects.
Further findings
BRAFV600E mutation prevalence
- Patients with BRAFV600E mutation
- 5102 (79.2%)
Gender
- Gender was not a significant factor in either tumor size subgroup
Original publication
The association between BMI and BRAFV600E mutation may differ by primary tumor size. Eur Thyroid J. Published 3 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →